It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's website on ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...

Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...